• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Nat Commun . Molecular basis of potent antiviral HLA-C-restricted CD8+ T cell response to an immunodominant SARS-CoV-2 nucleocapsid epitope

tetano

Editor, Senior Moderator
Nat Commun


. 2025 Aug 28;16(1):8062.
doi: 10.1038/s41467-025-63288-3. Molecular basis of potent antiviral HLA-C-restricted CD8[SUP]+[/SUP] T cell response to an immunodominant SARS-CoV-2 nucleocapsid epitope

Yoshihiko Goto[SUP] #[/SUP][SUP] 1 2 [/SUP], You Min Ahn[SUP] #[/SUP][SUP] 3 4 [/SUP], Mako Toyoda[SUP] 1 [/SUP], Hiroshi Hamana[SUP] 5 [/SUP], Yan Jin[SUP] 1 [/SUP], Yoshiki Aritsu[SUP] 1 [/SUP], Takeshi Nakama[SUP] 1 [/SUP], Yuka Tajima[SUP] 1 2 [/SUP], Janesha C Maddumage[SUP] 3 4 [/SUP], Huanyu Li[SUP] 1 [/SUP], Mizuki Kitamatsu[SUP] 6 [/SUP], Hiroyuki Kishi[SUP] 5 [/SUP], Akiko Yonekawa[SUP] 7 [/SUP], Dhilshan Jayasinghe[SUP] 3 4 [/SUP], Nobuyuki Shimono[SUP] 7 [/SUP], Yoji Nagasaki[SUP] 8 [/SUP], Rumi Minami[SUP] 9 [/SUP], Takashi Toya[SUP] 10 [/SUP], Noritaka Sekiya[SUP] 11 12 [/SUP], Yusuke Tomita[SUP] 2 [/SUP], Demetra S M Chatzileontiadou[SUP] 3 4 13 [/SUP], Hirotomo Nakata[SUP] 14 [/SUP], So Nakagawa[SUP] 15 [/SUP], Takuro Sakagami[SUP] 2 [/SUP], Takamasa Ueno[SUP] 1 [/SUP], Stephanie Gras[SUP] 16 17 18 [/SUP], Chihiro Motozono[SUP] 19 [/SUP]



Affiliations
Abstract

The emergence of SARS-CoV-2 Variants of Concern (VOC) is a major clinical threat; however, VOC remain susceptible to cytotoxic T lymphocyte (CTL) recognition. Therefore, it is crucial to identify potent CTL responses targeting conserved epitopes across VOCs. Here, we demonstrate that the nucleocapsid (N) protein induces efficient CTL responses in early pandemic COVID-19 convalescent donors. In the context of the HLA-A24-B52-C12 haplotype, prevalent in Japan, the KF9 peptide (N[SUB]266-274[/SUB]: KAYNVTQAF) is immunodominant and restricted by HLA-C*12:02. KF9-specific T cells are cytotoxic and suppress viral replication of both the ancestral and multiple VOC SARS-CoV-2. KF9-specific CD8[SUP]+[/SUP] T cells maintain effector memory and terminally differentiated phenotypes for 12 months post-infection and proliferate rapidly upon recall. We also determine the structure of a TCR in the context of the HLA-C*12:02-KF9 complex, providing a prototype for the interaction of HLA-C with viral peptides. Surprisingly, despite the TCR's high affinity, the CDR3β loop almost lacks contact with the KF9 peptide. These findings highlight the importance of conserved epitopes and the role of HLA-C molecules in controlling SARS-CoV-2 VOC.


 
Back
Top Bottom